Search
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalFurthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia [F3925], although other regional regulatory authorities like the EMA, among others, have not … serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible proposal that noradrenaline plays an
Hepatitis B Vaccine (Recombinant)
go.drugbank.com/drugs/DB11627ApprovedInvestigationalWithdrawnThe incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. … In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%.
Cefpodoxime
go.drugbank.com/drugs/DB01416ApprovedInvestigationalVet approvedCommonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. … Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors. … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved
Aluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalAluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. … An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
International brands: Alu-CapMixtures: Up and Up Antacid Anti Gas, Up and Up Antacid Anti Gas Regular StrengthGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]
Cetylpyridinium
go.drugbank.com/drugs/DB11073ApprovedInvestigationalIn these products, it generally mediates an antiseptic activity and protective action against dental plaque and reducing gingivitis. … Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays.
Zuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalIt is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.